Immune Design Corp. (NASDAQ:IMDZ) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 722,704 shares, a decrease of 65.5% from the October 13th total of 2,097,288 shares. Based on an average trading volume of 2,054,573 shares, the short-interest ratio is presently 0.4 days. Currently, 2.6% of the shares of the stock are sold short.
A number of analysts have recently commented on the stock. Zacks Investment Research cut shares of Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. ValuEngine cut shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $29.00 to $10.00 in a research note on Tuesday, October 17th. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. Finally, BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $13.19.
In related news, Director Peter Svennilson bought 2,681,000 shares of the business’s stock in a transaction dated Friday, October 27th. The stock was acquired at an average price of $4.10 per share, with a total value of $10,992,100.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Franklin M. Berger bought 25,000 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were bought at an average cost of $4.26 per share, with a total value of $106,500.00. Following the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at $213,000. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 5,300,000 shares of company stock valued at $21,874,900. Insiders own 20.70% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in Immune Design Corp. by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 8,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Immune Design Corp. during the 2nd quarter valued at about $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design Corp. during the 2nd quarter valued at about $118,000. Virtu KCG Holdings LLC purchased a new stake in Immune Design Corp. during the 2nd quarter valued at about $153,000. Finally, Dimensional Fund Advisors LP grew its stake in Immune Design Corp. by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 1,600 shares in the last quarter. 51.74% of the stock is owned by institutional investors.
Shares of Immune Design Corp. (IMDZ) opened at $4.40 on Friday. Immune Design Corp. has a one year low of $3.78 and a one year high of $13.05.
Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11. Immune Design Corp. had a negative net margin of 619.62% and a negative return on equity of 68.69%. The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.62 million. equities analysts predict that Immune Design Corp. will post -1.89 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Immune Design Corp. (IMDZ) Short Interest Update” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/11/18/immune-design-corp-imdz-short-interest-update.html.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.